(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 June 2003 (05.06.2003)

PCT

(10) International Publication Number
WO 03/045372 A1

(51) International Patent Classification[7]: A61K 31/195, 31/198, 31/525, A61P 41/00, A23L 1/305 // (A61K 31/525, 31:198, 31:195)

(21) International Application Number: PCT/US02/37354

(22) International Filing Date:
21 November 2002 (21.11.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/995,010 27 November 2001 (27.11.2001) US

(71) Applicant and
(72) Inventor: **BURZYNSKI, Stanislaw, R.** [US/US]; 9432 Old Katy Road, Suite 200, Houston, TX 77055 (US).

(74) Agent: **KAMMERER, Patricia, A.**; Howrey Simon Arnold & White, LLP, 750 Bering Drive, Houston, TX 77057-2198 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 03/045372 A1

**(54) Title:** FORMULATION OF AMINO ACIDS AND RIBOFLAVIN USEFUL TO REDUCE TOXIC EFFECTS OF CYTOTOXIC CHEMOTHERAPY

**(57) Abstract:** Pharmaceutical compositions effective in alleviating or reducing the effects of fatigue and weakness associated with cancer and cytotoxic cancer chemotherapy are disclosed. The pharmaceutical compositions of the present invention comprise riboflavin, effectors of the urea cycle in free form or pharmacologically acceptable salts thereof, and amino acids selected from the gorups of essential and non-essential amino acids, in free form or pharmaceutically acceptable salts thereof, suitably combined with appropriate carriers, diluents, or excipients. Also disclosed are methods of alleviating or reducing the effects of fatigue and weakness associated with cancer and cytotoxic cancer chemotherapy by administration of pharmaceutical compositions of the present invention.